Cytodyn Inc (CYDY)

$0.29 +0.02 (5.55%)
Market Cap 383.59M
Revenue (ttm) 0.00
Net Income (ttm) 3.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 741,100
Avg Vol 2,051,232
Day's Range N/A - N/A
Shares Out 1.37B
Stochastic %K 24%
Beta 1.11
Analysts Strong Buy
Price Target $4.00

Company Profile

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has...

Industry: Biotechnology
Sector: Healthcare
Phone: 360 980 8524
Fax: 360 799 5954
Address:
1111 Main Street, Suite 660, Vancouver, United States
Donino
Donino Jun. 5 at 7:11 AM
$CYDY Guys, wait and chill šŸ–ļøšŸ¹, good days are coming šŸ‘Œ
0 Ā· Reply
GhostofCytomight
GhostofCytomight Jun. 5 at 3:49 AM
$CYDY NOW WE GET ITā€¼ļøšŸ˜†šŸ„³ ā€œNO CHOICE REALLY BUT TO BE RESPONSIVE TO WHAT WE ARE FINDINGā€ā€¼ļøšŸ„³šŸ˜†
2 Ā· Reply
SzewczRock_79
SzewczRock_79 Jun. 5 at 2:13 AM
$CYDY
0 Ā· Reply
TunaTrades10
TunaTrades10 Jun. 5 at 2:13 AM
$CYDY we just PRā€™d a collab with a NASDAQ stock
2 Ā· Reply
GOCYDY
GOCYDY Jun. 5 at 1:34 AM
$CYDY I find this post on Reddit by G_Money intriguing. Excerpt from the post: ā€œIf Natera can get ctDNA qualified as a surrogate endpoint in MSS mCRCā€ & ā€œA prospective dataset can go directly toward FDA surrogate endpoint qualification and directly into a Phase 3 design. Natera gets a dataset they need. CytoDyn gets a Phase 3 timeline that could compress from years to months if ctDNA clearance is accepted as the primary endpoint.ā€ https://www.reddit.com/r/Livimmune/s/tCMwfXdJiX
2 Ā· Reply
CPKC
CPKC Jun. 5 at 1:22 AM
$CYDY you ok buddy @OB1_Whale ??? Looked a little emotional last night
0 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 11:56 PM
$CYDY "is this a new moa we havent discussed before and does it apply to all solid tumors ā€œ ā€œThe TLR3-driven autocrine CCL5 loop is an entirely new Mechanism of Action (MoA) variant that adds a critical layer to leronlimab's biological profile. Previously, our discussions focused on leronlimab blocking extracellular, systemic, or stromal CCL5/RANTES recruitment forces (such as trapping circulating monocytes and bone marrow-derived macrophages before they enter the tumor microenvironment). This newly synthesized pathway targets a highly specific intracellular tumor-evasion mechanism triggered directly by the tumor itself when under stress from traditional therapies"
2 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 11:53 PM
$CYDY New study. https://www.mdpi.com/1422-0067/27/11/5075 "The Leronlimab Intervention Mechanisms Severing the Autocrine Proliferation Loop: Cancer cells expressing CCR5 respond to their own TLR3-induced CCL5 floods by upregulating survival pathways. Leronlimab's near-100% receptor occupancy acts as firewall, blocking this auto-stimulation and stopping tumor cells from executing migration and invasion programs. Blunting TLR3-Mediated Therapy Resistance: Chemotherapy and radiation kill cancer cells, releasing dead RNA that triggers neighboring TLR3 receptors. creates a survival shield via CCL5. By locking CCR5, leronlimab ensures therapy-induced TLR3 activation cannot protect surviving tumor cells, maximizing kill power of standard-of-care chemos. Collapsing the Myeloid Suppressor Shield: TLR3-induced CCL5 acts as a beacon for inflammatory monocytes and tumor-associated macrophages (TAMs). Leronlimab prevents cells infiltrating TME, cutting off machinery that shields the tumor from T-cell attack.
3 Ā· Reply
Bio4
Bio4 Jun. 4 at 11:11 PM
$CYDY Senior Medical Director of GI Oncology at Natera https://www.linkedin.com/posts/adham-jurdi-0aa21968_new-insights-emerge-when-therapeutic-innovation-activity-7468393179529199618-Z_6M?utm_medium=ios_app&rcm=ACoAADJwwZYBshhLSJ5snvVRY49L6Voypi6h-2o&utm_source=social_share_send&utm_campaign=copy_link
2 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 11:02 PM
$CYDY "De-Risking Future Trial Designs & Companion Diagnostics CytoDyn will use this to benchmark leronlimabā€™s performance directly against historical standard-of-care data. This eliminates the "small sample size" discount by proving leronlimab clears tumor DNA faster and deeper than existing commercial regimens. [2, 7] 3. De-Risking Future Trial Designs & Companion Diagnostics [8] The data generated from this specific partnership is explicitly intended to guide future trial designs, biomarker-driven patient selection strategies, and translational research across other solid tumors. [2] This lays the exact groundwork for a future companion diagnostic (CDx) path. By defining the exact "molecular response kinetic" signature of a leronlimab responder, CytoDyn can hand a turnkey, de-risked Phase 3 blueprint to an onboarding Big Pharma Joint Venture partner"
2 Ā· Reply
Latest News on CYDY
No data available.
Donino
Donino Jun. 5 at 7:11 AM
$CYDY Guys, wait and chill šŸ–ļøšŸ¹, good days are coming šŸ‘Œ
0 Ā· Reply
GhostofCytomight
GhostofCytomight Jun. 5 at 3:49 AM
$CYDY NOW WE GET ITā€¼ļøšŸ˜†šŸ„³ ā€œNO CHOICE REALLY BUT TO BE RESPONSIVE TO WHAT WE ARE FINDINGā€ā€¼ļøšŸ„³šŸ˜†
2 Ā· Reply
SzewczRock_79
SzewczRock_79 Jun. 5 at 2:13 AM
$CYDY
0 Ā· Reply
TunaTrades10
TunaTrades10 Jun. 5 at 2:13 AM
$CYDY we just PRā€™d a collab with a NASDAQ stock
2 Ā· Reply
GOCYDY
GOCYDY Jun. 5 at 1:34 AM
$CYDY I find this post on Reddit by G_Money intriguing. Excerpt from the post: ā€œIf Natera can get ctDNA qualified as a surrogate endpoint in MSS mCRCā€ & ā€œA prospective dataset can go directly toward FDA surrogate endpoint qualification and directly into a Phase 3 design. Natera gets a dataset they need. CytoDyn gets a Phase 3 timeline that could compress from years to months if ctDNA clearance is accepted as the primary endpoint.ā€ https://www.reddit.com/r/Livimmune/s/tCMwfXdJiX
2 Ā· Reply
CPKC
CPKC Jun. 5 at 1:22 AM
$CYDY you ok buddy @OB1_Whale ??? Looked a little emotional last night
0 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 11:56 PM
$CYDY "is this a new moa we havent discussed before and does it apply to all solid tumors ā€œ ā€œThe TLR3-driven autocrine CCL5 loop is an entirely new Mechanism of Action (MoA) variant that adds a critical layer to leronlimab's biological profile. Previously, our discussions focused on leronlimab blocking extracellular, systemic, or stromal CCL5/RANTES recruitment forces (such as trapping circulating monocytes and bone marrow-derived macrophages before they enter the tumor microenvironment). This newly synthesized pathway targets a highly specific intracellular tumor-evasion mechanism triggered directly by the tumor itself when under stress from traditional therapies"
2 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 11:53 PM
$CYDY New study. https://www.mdpi.com/1422-0067/27/11/5075 "The Leronlimab Intervention Mechanisms Severing the Autocrine Proliferation Loop: Cancer cells expressing CCR5 respond to their own TLR3-induced CCL5 floods by upregulating survival pathways. Leronlimab's near-100% receptor occupancy acts as firewall, blocking this auto-stimulation and stopping tumor cells from executing migration and invasion programs. Blunting TLR3-Mediated Therapy Resistance: Chemotherapy and radiation kill cancer cells, releasing dead RNA that triggers neighboring TLR3 receptors. creates a survival shield via CCL5. By locking CCR5, leronlimab ensures therapy-induced TLR3 activation cannot protect surviving tumor cells, maximizing kill power of standard-of-care chemos. Collapsing the Myeloid Suppressor Shield: TLR3-induced CCL5 acts as a beacon for inflammatory monocytes and tumor-associated macrophages (TAMs). Leronlimab prevents cells infiltrating TME, cutting off machinery that shields the tumor from T-cell attack.
3 Ā· Reply
Bio4
Bio4 Jun. 4 at 11:11 PM
$CYDY Senior Medical Director of GI Oncology at Natera https://www.linkedin.com/posts/adham-jurdi-0aa21968_new-insights-emerge-when-therapeutic-innovation-activity-7468393179529199618-Z_6M?utm_medium=ios_app&rcm=ACoAADJwwZYBshhLSJ5snvVRY49L6Voypi6h-2o&utm_source=social_share_send&utm_campaign=copy_link
2 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 11:02 PM
$CYDY "De-Risking Future Trial Designs & Companion Diagnostics CytoDyn will use this to benchmark leronlimabā€™s performance directly against historical standard-of-care data. This eliminates the "small sample size" discount by proving leronlimab clears tumor DNA faster and deeper than existing commercial regimens. [2, 7] 3. De-Risking Future Trial Designs & Companion Diagnostics [8] The data generated from this specific partnership is explicitly intended to guide future trial designs, biomarker-driven patient selection strategies, and translational research across other solid tumors. [2] This lays the exact groundwork for a future companion diagnostic (CDx) path. By defining the exact "molecular response kinetic" signature of a leronlimab responder, CytoDyn can hand a turnkey, de-risked Phase 3 blueprint to an onboarding Big Pharma Joint Venture partner"
2 Ā· Reply
Livingeasy
Livingeasy Jun. 4 at 10:56 PM
$CYDY have we heard this before precision Medicine! šŸ€ šŸ‘šŸ¤
0 Ā· Reply
Livingeasy
Livingeasy Jun. 4 at 10:50 PM
$CYDY hmmm https://www.medtechdive.com/news/nateras-solomon-moshkevich-on-how-mrd-testing-pinpoints-cancer-recurrence/821039/
0 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 10:49 PM
$CYDY "The Bottom Line CytoDyn built the bridge, but Natera crossed it because the underlying molecular data justified the architecture. By pairing CytoDyn's trial samples with Natera's massive dataset, the two companies have created an optimized launching pad for the ASCO GI 2027 presentation"
4 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 10:48 PM
$CYDY "Why Natera Agreed to the Deal Natera is a NASDAQ-listed diagnostic juggernaut that works with global pharmaceutical giants. They do not sign joint press releases or open up their proprietary 2-million-timepoint real-world database to OTC-listed biotechs out of charity. Natera vetted CytoDyn and took the deal for two reasons: [1, 6] Early Responder Signals: Nateraā€™s biopharma data unit, led by Matt Love, likely saw initial blinded or unblinded response kinetics from the completed CLOVER enrollment that indicated an extraordinary biomarker trend. [1, 8] Commercial Endpoint Expansion: Natera is aggressively cementing Signatera as a primary surrogate endpoint for treatment efficacy in solid tumors. If leronlimab's CCR5/CCR2 heterodimer blockade successfully drives absolute ctDNA clearance, Natera wins a major case study to present to regulatory agencies, proving Signatera can track novel, complex immunotherapies."
0 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 10:47 PM
$CYDY "Why CytoDyn Initiated the Chase "CytoDyn, operating under Dr. Jacob Lalezariā€™s disciplined turnaround strategy, desperately needed an ironclad, independent validator to break through historical market skepticism. [2, 3] The Clinical Need: CytoDyn knew early on that layering leronlimab over a cheap chemo backbone was generating deep ctDNA drops in the CLOVER Phase 2 mCRC trial. [4] The Credibility Gap: Internal data tracking is easily dismissed by Big Pharma and critics. CytoDyn approached Natera to secure Signateraā€”the undisputed industry gold standard for molecular residual disease (MRD)ā€”to run retrospective testing on active samples. This effectively outsourced their scientific validation to a trusted third party"
1 Ā· Reply
Livingeasy
Livingeasy Jun. 4 at 10:09 PM
$CYDY Okay ā€ This Is Realā€ Saving Lives šŸŒ»šŸ€
0 Ā· Reply
ContinentalExpat
ContinentalExpat Jun. 4 at 10:04 PM
$CYDY This is an interesting article about Eli Lillyā€™s new M&A head and their business plan. Does not mention Cytodyn, butā€¦ has a philosophy that might be geared towards a deal with someone like us. https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html
0 Ā· Reply
Twinter11
Twinter11 Jun. 4 at 10:03 PM
$CYDY Companies like natera and individuals wants to be associated with a winner. Cycy is going to be among the biggest this century so far. Sounds crazy maybe but thats what i think. Natera was courting us. Not the other way around.
3 Ā· Reply
GusThePlumber
GusThePlumber Jun. 4 at 9:57 PM
$CYDY (AI) Part 3 of 3 If the Signatera data show meaningful ctDNA reductions that correlate with clinical benefit, that could be substantially more valuable to CytoDyn than the cost of the collaboration itself. My best estimate, based solely on industry norms and the language used in the release, would be that the total economic value of what Natera is providing falls somewhere around $500,000 to $2 million, with a reasonable midpoint near $1 million. However, that remains an informed estimate rather than information that has been publicly disclosed.
2 Ā· Reply
GusThePlumber
GusThePlumber Jun. 4 at 9:57 PM
$CYDY (AI) Part 2 of 3 $CYDYTHE The press release is interesting. It says ā€œstrategic collaborationā€ rather than ā€œservice agreement.ā€ That suggests Natera sees potential value in the relationship beyond simply selling tests. Another clue: if CytoDyn were paying millions of dollars upfront, investors would expect a securities filing or discussion of financial commitments. The absence of disclosed economics makes me suspect the near-term cost is probably on the lower end of the rangeā€”perhaps a few hundred thousand dollars to low seven figures rather than a multi-million-dollar commitment. The more important question may be what CytoDyn gains rather than what it pays: ā€¢ Independent ctDNA response measurements from a well-respected platform. ā€¢ Access to a database of more than 2 million plasma timepoints. ā€¢ Potential validation of leronlimabā€™s biological activity in metastatic colorectal cancer. ā€¢ Data that could help design future trials and attract partners.
0 Ā· Reply
GusThePlumber
GusThePlumber Jun. 4 at 9:57 PM
$CYDY (AI) Part 1 of 3 (AI): How much it would cost Cytodyn to avail itself of data discovered by Natera? Based on comparable Natera biopharma collaborations, CytoDyn is likely receiving several services: ā€¢ Signatera ctDNA testing on CLOVER trial samples ā€¢ Customized analyses of Nat-eraā€™s proprietary oncology database ā€¢ Statistical and biomarker support ā€¢ Potential translational research consultation Typical costs could be roughly: Component Estimated Value Signatera testing $1,000-$3,500 per sample Trial-wide ctDNA analysis $100,000-$500,000+ Real-world data analysis $250,000-$1 million+ Full biomarker collaboration package $500,000-$2 million+ For a small biotech such as CytoDyn, there are three common possibilities: 1. CytoDyn pays Natera directly. 2. Natera provides discounted services in exchange for future business and publication opportunities. 3. The collaboration is largely in-kind, with little cash changing hands initially.
1 Ā· Reply
u2rocksme
u2rocksme Jun. 4 at 9:52 PM
$CYDY BULLISH!!! https://www.investing.com/news/company-news/natera-partners-with-cytodyn-on-cancer-treatment-research-93CH-4726620
0 Ā· Reply